ArticleFrontiers in oncology2022
A Novel Stool Methylation Test for the Non-Invasive Screening of Gastric and Colorectal Cancer.
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Diagnostic value of genetic and epigenetic biomarker panels for colorectal cancer detection: a systematic review.International journal of colorectal disease · 2025Pooled it
- Artificial Intelligence in Gastric Cancer: Diagnostic, Prognostic, and Predictive Developments, Evidence Maturity, and Translational Challenges.Cancer reports (Hoboken, N.J.) · 2026Review
- A scoping review of DNA methylation biomarkers for non-invasive detection of colorectal cancer at the CpG site level.Clinical epigenetics · 2026Article
- Development of an application for colorectal cancer prediction using SDC2 and TFPI2 methylation: an opportunity for early and noninvasive diagnosis in Latin-America.Frontiers in molecular biosciences · 2026Article
- The Role of DNA Methylation in Gastrointestinal Disease: An Expanded Review of Malignant and Nonmalignant Gastrointestinal Diseases.Gastroenterology · 2025Review
- Advances in the diagnosis of colorectal cancer: the application of molecular biomarkers and imaging techniques: a literature review.Annals of medicine and surgery (2012) · 2025Review
- Combined Methylation Analysis of SDC2 and TFPI2 in Plasma: A Noninvasive Liquid Biopsy Approach for Early Detection of Colorectal Polyp.International journal of molecular and cellular medicine · 2025Article
- Diagnostic value of multi-gene methylation in colorectal cancer screening.Frontiers in oncology · 2025Article
- Extensive methylation analysis of circulating tumor DNA in plasma of patients with gastric cancer.Scientific reports · 2024Article
- Comprehensive Multiomics Analyses Establish the Optimal Prognostic Model for Resectable Gastric Cancer : Prognosis Prediction for Resectable GC.Annals of surgical oncology · 2024Article
- DNA methylation drives a new path in gastric cancer early detection: Current impact and prospects.Genes & diseases · 2024Review
- Advancements in the clinical application of gene methylation for early cancer detection.Frontiers in epigenetics and epigenomics · 2024Review
- SDC2 Stabilization by USP14 Promotes Gastric Cancer Progression through Co-option of PDK1.International journal of biological sciences · 2023Article
- Combining methylated SDC2 test in stool DNA, fecal immunochemical test, and tumor markers improves early detection of colorectal neoplasms.Frontiers in oncology · 2023Article
- An overview of DNA methylation markers for early detection of gastric cancer: current status, challenges, and prospects.Frontiers in genetics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Because of poor compliance or low sensitivity, existing diagnostic approaches are unable to provide an efficient diagnosis of patients with gastric and colorectal cancer. Here, we developed the ColoCaller test, which simultaneously detects the methylation status of the SDC2, TFPI2, WIF1, and NDRG4 genes in stool DNA, to optimize the screening of gastric and colorectal cancer in high-risk populations. Methods: A total of 217 stool samples from patients with gastrointestinal cancer and from patients with negative endoscopy were prospectively collected, complete with preoperative and postoperative clinical data from patients. The methylation of these samples was detected using ColoCaller, which was designed by selecting CpGs with a two-step screening strategy, and was interpreted using a prediction model built using libSVM to evaluate its clinical value for gastric and colorectal cancer screening. Results: Compared to pathological diagnosis, the sensitivity and specificity of the ColoCaller test in 217 stool DNA samples were 95.56% and 91.86%, respectively, for colorectal cancer, and 67.5% and 97.81%, respectively, for gastric cancer. The detection limit was as low as 1% in 8 ng of DNA. Conclusion: In this study, we developed and established a new test, ColoCaller, which can be used as a screening tool or as an auxiliary diagnostic approach in high-risk populations with gastric and colorectal cancer to promote timely diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.